GlaxoSmithKline originally invested in the vaccine developer in 2012.

Cambridge University spin-out Owlstone is set to trial cancer diagnostic test kits in NHS hospitals.

Queensland life sciences spin-out Vaxxas secures A$25m ($20m) for needleless injection technologies.

AbbVie and Abbott-backed biotechnology developer AuraSense closed the $13.6m firs tranche of the round in June last year.

Siemens and Merck-backed Aventura has developed a platform using electronic health records to improve workflow in hospitals.

Andrew Hopkins, professor and spin-out founder from Dundee University, picks up entrepreneurial business leadership prize.

Stockholm-based Biolin Scientific Holding signs licensing agreement with Munich spin-out Nanion.

The genome sequencing technology developer raised the funding from backers including the venture capital arms of Mitsubishi and Mizuho.

Intel-backed transplant surveillance technology company CareDx has raised $40m in its initial public offering.